{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-026506","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2026-06-26T12:30:33+00:00","discovered_at":"2026-06-26T12:35:00.356824+00:00","generated_at":"2026-06-26T12:35:13.533052+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"BridgeBio director Scott resigns at annual meeting; stockholders approve 2M share increase in stock plan","bullets":["Dr. Randal W. Scott resigned as Class I director effective June 22, 2026, upon term completion, citing no disagreement.","Stockholders approved amending 2021 Stock Option Plan to increase reserved shares by 2,000,000.","Elected Class I directors: Momtazee, McCormick, Valantine; all received >129M votes for.","Non-binding advisory vote on executive compensation approved (152.9M for); 1-year frequency endorsed."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-026506","json":"https://secwatch.observer/filing/0001140361-26-026506.json","markdown":"https://secwatch.observer/filing/0001140361-26-026506.md","text":"https://secwatch.observer/filing/0001140361-26-026506.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126026506/0001140361-26-026506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126026506/ef20076710_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T12:35:13.533052+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}